An observational study in Segmental Exclusion Syndrome, Complex Regional Pain Syndrome (CRPS) and Upper Limb Neglect (Peripheral), sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Complex Regional Pain Syndromes with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Complex Regional Pain Syndromes · France.
Among the 17 studies in Complex Regional Pain Syndromes with a site in France, this one is the only one that started in 2025, is one of 4 observational ones, and was the 15th registered.
206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.
Browse Complex Regional Pain Syndromes studies →6 of the 17 studies in Complex Regional Pain Syndromes with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Polyclinique de l'Europe · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 12–20
Elsan · Sites in France
Ages 18–75
Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 41 Complex Regional Pain Syndromes studies recruiting now, 19 (46%) set no upper age limit and 16 (39%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 58 across 44 observational studies indexed under Complex Regional Pain Syndromes.
Median enrollment 60 across the 13 interventional studies, 33 across the 4 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est has 1 study filed under Complex Regional Pain Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Complex Regional Pain Syndromes with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07361692Polyclinique de l'EuropeEffectiveness of Transcranial Direct Current Stimulation (tDCS) in the Management of Complex Regional Pain Syndrome | 2027-06-01 |
| NCT07349173Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord EstPeripersonal Space Representation in Upper Limb Segmental Exclusion | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Complex Regional Pain Syndromes with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The study hypothesizes that this syndrome leads to a modification (shrinkage) of the PPS representation. Participants will perform reachability judgments in a Virtual Reality (VR) environment.
Segmental exclusion syndrome often occurs after limb trauma and manifests as a neglect-like behavior of peripheral origin, sometimes associated with Complex Regional Pain Syndrome (CRPS). The study explores whether the lack of limb use affects the representation of peripersonal space (PPS)-the space immediately surrounding the body where interactions with objects occur.
The study is monocentric, observational, with a matched control group. Participants will undergo:
Clinical assessment (questionnaires on pain, anxiety, body perception, and kinesiophobia).
A Virtual Reality (VR) test (approx. 40 minutes). In VR, participants will judge whether a cylinder presented at different distances and angles is reachable without moving (Perceived Reachable Distance - DMA-p). This will be compared to their Real Reachable Distance (DMA-r).
The goal is to measure the error of judgment to assess PPS representation and check for correlations with body schema disturbances or functional impairment
he study population consists of two groups recruited at the Institut Régional de Réadaptation (Centre Louis Pierquin, UGECAM Nord-Est) in Nancy, France.
Patients with Exclusion: Participants are selected from patients receiving routine care (full hospitalization or day hospital) at the center. They are identified based on a functional assessment ("Bilan 400 points") showing specific impairments related to unilateral upper limb exclusion evolving for more than 3 months.
Healthy Controls: Asymptomatic volunteers are recruited through the social or family network of the investigators and current participants, as well as via posters displayed in the UGECAM centers.
Inclusion Criteria (patients):
Inclusion Criteria (Controls):
Exclusion Criteria (All):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients presenting with unilateral segmental exclusion of the upper limb or part of the hand evolving for more than 3 months.
Behavioral: Reachability Judgment Task in VR.
symptomatic volunteers with no history of upper limb impairment with sequelae.
Behavioral: Reachability Judgment Task in VR.
Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).
Judgment Error of Reachability
The Judgment Error of Reachability is a single composite metric calculated as: ((DMA-p - DMA-r) / DMA-r) × 100, expressed as a percentage (%). Both DMA-p (Perceived Maximum Reachable Distance) and DMA-r (Real Maximum Reachable Distance) are measured in centimeters, and their ratio yields a single dimensionless percentage score.
Time frame: Day 1 (During the 40-minute VR assessment)
Body Perception Disturbance Score
Assessed using the Bath CRPS Body Perception Disturbance Scale (French version). Scores range from 0 to 57, with higher scores indicating greater disturbance.
Time frame: Day 1 (Before VR task)
Functional Impairment Score (400-Point Hand Assessment)
Evaluated using the 400-Point Hand Assessment, which measures functional hand use. The score ranges from 0 to 400, where higher scores indicate better functional performance (better outcome).
Time frame: Day 1
Anxiety and Depression Score (HAD)
Hospital Anxiety and Depression Scale. Scores range from 0 to 21 for each dimension (Anxiety and Depression).
Time frame: Day 1
Kinesiophobia Score (Tampa Scale)
Tampa Scale for Kinesiophobia (TSK). Assesses fear of movement. Scores range to 68; \>40 indicates significant kinesiophobia.
Time frame: Day 1
Pain Catastrophizing Score (PCS)
Pain Catastrophizing Scale. Scores range from 0 to 52.
Time frame: Day 1
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Complex Regional Pain Syndromes →
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est